Celcuity, which is developing live cell diagnostic tests for cancer patients, raised $22.8 million by offering 2.4 million shares at $9.50, within the range of $8 to $10. It originally filed to offer 2.0 million shares. At $9.50, the pre-revenue company commands a fully diluted market cap of $94 million. Celcuity plans to list on the Nasdaq under the symbol CELC. Craig-Hallum Capital Group acted as a lead manager on the deal.
